Poster Abstract Session:
219. Antibacterial Safety
Saturday, October 29, 2016: 12:30 PM-2:00 PM
Room: Poster Hall

Learning Objectives:

.

Tracks: Adult ID

Presentations:
1799
Prevalence of Documented Beta-lactam Allergies in the Veterans Affairs Health System from 2000 - 2014. 
Kevin Mcconeghy, Pharm.D. ; Haley Morrill, PharmD ; Aisling Caffrey, PhD, MS ; Amal N. Trivedi, MD ; David Dosa, MD, MPH ; Kerry Laplante, Pharm.D., FCCP
1800
Characterizing Cefepime Neurotoxicity: A Systemic Review
Ayesha Appa, MD ; Rupali Jain, Pharm.D. ; Robert Rakita, MD ; Shahin Hakimian, MD ; Paul Pottinger, MD, FIDSA
Posters
  • 1800_IDWkPoster_Appa.pdf (204.5 kB)
    • 1801
    The Importance of Postmarketing Surveillance in the Identification of Early Safety Signals of Medication Errors in Patients Receiving a New Combination Antibiotic
    Ann Marie Marr, Pharm.D. ; Amy Morgan, Pharm.D., BCPS ; Maribel Salas, MD, DSc, MSc, FACP
    Posters
  • marrann_191645-0001-ID_Week_Poster_v2.00.pdf (652.0 kB)
    • 1802
    Development of Acute Kidney Injury in Patients treated with Polymyxin B Compared to Colistimethate Sodium
    Ryan L. Crass, PharmD ; W. Cliff Rutter, PharmD ; Donna R. Burgess, RPh ; Craig a. Martin, PharmD, MBA ; David S. Burgess, PharmD, FCCP
    1803
    Risk Factors for Acute Kidney Injury in Patients Treated with Polymyxin B: Experience from 139 Cases at a Tertiary University Hospital in Colombia
    Carlos Gomez, MD ; Jackeline Barreto, MD ; Johanna Osorio, MD ; Luis C Alvarez, MD ; Claudia F Samboni, MD ; Jorge a Ramos, RN ; Dagoberto Santofimio, MD ; Yudi S Benavides, MD ; Roso Tellez, MD ; Lina Candelo, MD
    Posters
  • CAG 1803 IDweek 2016.pdf (1.8 MB)
    • 1804
    Nephrotoxicity associated with intravenous (IV) polymyxin B (PMB) once versus twice daily dosing
    Nabeela Ahmed, PharmD ; Marco R. Scipione, PharmD ; John Papadopoulos, PharmD ; Daniel Eiras, MD, MPH ; Yanina Dubrovskaya, PharmD
    Posters
  • PMB%20IDSA%20Poster_Final%2010.21.16_PDF.pdf (280.3 kB)
    • 1805
    Vancomycin plus Piperacillin/Tazobactam and Acute Kidney Injury in Adults: A Systematic Review and Meta-analysis
    Megan Luther, Pharm.D. ; Aisling Caffrey, PhD, MS ; David Dosa, MD, MPH ; Thomas P. Lodise, PharmD, PhD ; Kerry Laplante, Pharm.D., FCCP
    1806
    Comparative nephrotoxicity rates between colistimethate sodium and polymyxin B
    Pavithra Srinivas, PharmD, BCPS ; Stephanie Pouch, MD, MS ; Anthony T. Gerlach, PharmD, BCPS, FCCM, FCCP ; Claire V. Murphy, PharmD, BCPS ; Jessica E. Johnston, MS, MPH ; Debra a. Goff, PharmD, FCCP ; Karri a. Bauer, PharmD, BCPS
    Posters
  • Nephrotox CMSvsPB_IDWeek 2016 Poster_FINAL.pdf (241.8 kB)
    • 1807
    Interference of Oritavancin on Coagulation Tests as Assessed In vitro and in a Phase 1 Study of Normal Healthy Volunteers
    Adam Belley, Ph.D. ; Richard Robson, MBChB ; John Francis, PhD ; Dot Adcock, MD ; Stefan Tiefenbacher, PhD ; Christopher M. Rubino, Pharm.D. ; Greg Moeck, Ph.D. ; David Sylvester, BSc ; Michael Dudley, PharmD, FIDSA ; Jeff Loutit, MBChB
    Posters
  • Belley et al_1807_final.pdf (441.6 kB)
    • 1808
    WCK 4873 (Nafithromycin): Assessment of in vitro Human CYP Inhibitory Potential of a Novel Lactone-ketolide
    Rajesh Chavan, MSc. ; Vineet Zope, Mpharm ; Ravindra Yeole, PhD ; Mahesh Patel, PhD
    Posters
  • Poster A 21Oct 16.pdf (231.3 kB)
    • 1809
    Drug Induced Hemolytic Anemia From Ceftazidime/Avibactam, A New Old Antimicrobial: A Case Report.
    Kimberly D. Leuthner, PharmD ; Kristin Buechler, PharmD ; Ammar Yousif, MD ; Shadaba Asad, MD
    Posters
  • IDweek Poster 10-6-16.pdf (622.4 kB)
    • 1810
    Statin Coadministration Increases the Risk for Development of Daptomycin-Induced Myopathy
    Ryan Dare, MD, MS ; Chad Tewell, MD ; Bryan Harris, MD, MPH ; George Nelson, MD ; Patty Wright, MD, FIDSA ; Thomas Talbot, MD, MPH, FIDSA, FSHEA
    Posters
  • ID Week Dapto.png (980.8 kB)
    • 1811
    Incidence of Acute Kidney Injury in Pediatric Oncology Patients Receiving Combination Therapy with Vancomycin and Piperacillin-tazobactam or Cefepime
    Alaina Burns, Pharm.D. ; Veronica Nguyen, Pharm.D., BCPS, BCPPS ; Megan Smith, Pharm.D., BCPS, BCPPS ; Kyana Stewart, PharmD, BCPS ; Theodore Laetsch Jr., M.D.
    Posters
  • 1811.Incidence of AKI in Pediatric Oncology Patients Receving Combination Therapy with VPT or VC.pdf (506.0 kB)
    • 1812
    Is there a Difference in Acute Kidney Injury Incidence Among Patients Treated with Piperacillin-tazobactam or Levofloxacin?
    W. Cliff Rutter, PharmD ; David S. Burgess, PharmD, FCCP
    Posters
  • LEV PTZ poster.pdf (728.3 kB)
    • 1813
    Difference in Nephrotoxicity between Nafcillin and Piperacillin-Tazobactam
    Sonali K. Patel, PharmD, MPH ; W. Cliff Rutter, PharmD ; Daniela C. Moga, MD, PhD ; Craig Martin, PharmD, MBA
    Posters
  • Sonali Patel Poster.pdf (395.1 kB)
    • 1814
    Comparative Rates of Nephrotoxicity in Patients Treated with Piperacillin-tazobactam and Meropenem: a Retrospective Cohort Study.
    W. Cliff Rutter, PharmD ; David S. Burgess, PharmD, FCCP
    Posters
  • MEM PTZ poster v2.pdf (733.6 kB)
    • 1815
    Acute Kidney Injury in Patients Treated with Beta-lactam/Beta-lactamase Inhibitor Combinations
    W. Cliff Rutter, PharmD ; David S. Burgess, PharmD, FCCP
    Posters
  • AS PTZ poster.pdf (721.0 kB)

    • CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 Credit™

    ACPE Credits:

    ACPE Number:


    See more of: Poster Abstract Session
    << Previous Session | Next Session >>

    Findings in the abstracts are embargoed until 12:01 a.m. CDT, Wednesday Oct. 26th with the exception of research findings presented at the IDWeek press conferences.